HBeAg 양성 만성간염 환자에서 항바이러스 치료 중단 후 지속적인 관해에 대한 예측 인자Predictive Factors for Sustained Remission after Discontinuation of Antiviral Therapy in Patients with HBeAg-positive Chronic Hepatitis B
- Other Titles
- Predictive Factors for Sustained Remission after Discontinuation of Antiviral Therapy in Patients with HBeAg-positive Chronic Hepatitis B
- Authors
- 전백규; 이세환; 김홍수; 김상균; 김영석; 김부성; 정승원; 장재영; 김영돈; 천갑진
- Issue Date
- 2016
- Publisher
- 대한소화기학회
- Keywords
- Treatment; Chronic hepatitis B; Discontinuation; Remission; Relapse
- Citation
- 대한소화기학회지, v.67, no.1, pp 28 - 34
- Pages
- 7
- Journal Title
- 대한소화기학회지
- Volume
- 67
- Number
- 1
- Start Page
- 28
- End Page
- 34
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/9902
- ISSN
- 1598-9992
2233-6869
- Abstract
- Background/Aims: The optimal timing for discontinuing oral antiviral therapy in patients with HBeAg-positive chronic hepatitis B (CHB) is unclear. The aim of our study was to investigate sustained remission after stopping antiviral therapy in patients with HBeAg-positive CHB.
Methods: We analyzed the medical records of 58 patients who were HBeAg-positive and had discontinued antiviral therapy. Antiviral therapy was discontinued after HBeAg seroconversion and HBV DNA negativity for 6-12 months with consolidation therapy. Virologic relapse was defined as an increase in serum HBV DNA >2,000 IU/mL.
Results: No difference was observed between the virologic non-relapse and virologic relapse groups in baseline HBV DNA level (p=0.441) or duration of seroconversion (p=0.070). Time-to-undetectable HBV DNA during treatment was shorter in the virologic non-relapse group (29 patients) compared to the relapse group (29 patients) (4.9±2.6 vs. 13.2±12.7 months; p<0.01). Cumulative relapse rates were 12.7 in month 3, 32.7 in month 6, 47.3 in month 12, and 52.7% in month 18. We determined by multivariate analysis that the consolidation period (≥18 months, p=0.020) and early virologic response (HBV DNA <20 IU/mL) at six months during antiviral therapy (p=0.017) were significant predictors for sustained remission.
Conclusions: A consolidation period of at least 18 months and early virological response at six months during antiviral therapy were associated with sustained remission in patients with HBeAg-positive CHB after treatment.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Internal Medicine > 1. Journal Articles
- College of Medicine > Department of Internal Medicine > 1. Journal Articles
- College of Medicine > Department of Internal Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.